Metrics as of 10/13/2026, 06:55 PM (Berlin time), refresh in progress.
Verrica Pharmaceuticals Stock
Verrica Pharmaceuticals Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Jayson Rieger
- Employees
- 76
- Market cap
- $62 M
- IPO
- 15/06/2018
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for…
Verrica Pharmaceuticals stock: price history
1D
-10.7%
1W
-15.0%
1M
-27.1%
6M
-37.4%
YTD
-56.9%
1Y
-12.7%
2Y
-73.3%
5Y
-97.1%
10Y
–
Next earnings date
Next earnings date
13/11/2026 (in 27 days)
Volatility around earnings
~32% stronger price swings than usual
Ask the agents about Verrica Pharmaceuticals
Analyst assessment of Verrica Pharmaceuticals
PRICE TARGET LOW
US$9.00
CONSENSUS
US$9.00
MEDIAN
US$9.00
PRICE TARGET HIGH
US$9.00
0
STRONG BUY
6
BUY
4
HOLD
0
SELL
0
STRONG SELL
10
TOTAL · Buy
As of: 18/12/2025
Verrica Pharmaceuticals stock metrics
P/E
-2.06
P/B
17.71
EV/EBITDA
-1.95
RETURN ON EQUITY
-305.4%
NET MARGIN
-224.4%
DEBT/EQUITY
0.42
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
51.2%
FLOAT SHARES
8,803,860
AVG. DAILY VOLUME (30D)
49,158
Insider transactions (SEC)
Kirby John J.
Rosenberg Noah L.
Rosenberg Noah L.
Rieger Jayson
Rieger Jayson
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Verrica Pharmaceuticals stock
What does Verrica Pharmaceuticals do?
Verrica Pharmaceuticals Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Jayson Rieger, the company employs around 76 people.
The IPO was on 15/06/2018; the stock trades on NASDAQ under the ticker VRCA.
What do analysts say about Verrica Pharmaceuticals stock?
10 analysts rate the stock, the consensus is Buy (as of 18/12/2025).
The average price target is US$9.00, ranging from US$9.00 to US$9.00, with a median of US$9.00.
This is an external assessment, not a statement by Market Jury.
When does Verrica Pharmaceuticals report next?
The next earnings date is 13/11/2026.
Around past earnings, price swings were roughly 32% stronger than usual.
Does Verrica Pharmaceuticals pay a dividend?
No, Verrica Pharmaceuticals currently does not pay a dividend.
Which stocks are comparable to Verrica Pharmaceuticals?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Verrica Pharmaceuticals stock analyzed?
Clicking "Analyze stock" lets five strategies assess Verrica Pharmaceuticals against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.